WeVote
Log In

Bill

Bill

HB 4593

Relating to the provision of an abortion-inducing drug.

89th Legislature (2025) Introduced by Ellen Troxclair

Texas bill addressing medication abortion drug regulations; specific provisions unclear pending committee review and full text availability.

Referred to Public Health
#abortion(i0005) #healthcareproviders(i0387) #health--general(i0385) #medicine&prescriptiondrugs(s7338) #occupationalregulation--healthoccupations(i0540) #pregnancy&childbirth(s0294)
0
WeVote Research Nonpartisan
Bill Summary · HB 4593

Legislative bill overview

HB 4593 relates to regulations governing medication abortion (abortion-inducing drugs) in Texas. Without access to the full bill text, the specific provisions—whether expanding access, restricting use, modifying protocols, or changing oversight mechanisms—cannot be precisely detailed. The bill was filed in March 2025 and referred to the Public Health Committee in early April.

Why is this important

Medication abortion represents approximately 50% of all U.S. abortions and is a central healthcare policy issue. Texas has some of the nation's most restrictive abortion laws, making any legislation in this area substantively significant for healthcare access, medical practice standards, and reproductive rights in the state.

Potential points of contention

  • Existing Texas restrictions: Texas already prohibits abortion after six weeks of pregnancy and has strict regulations on medication abortion protocols, so the bill's specific approach to modification will determine stakeholder positions
  • Medical practice standards vs. legislative mandate: Disagreement over whether state law should dictate medication abortion procedures versus allowing physician-determined protocols consistent with FDA guidance
  • Access equity: Depending on provisions, potential disparate impacts on rural, low-income, or underserved populations' healthcare options

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.